Last reviewed · How we verify
TFP block ropivacaine
TFP block ropivacaine, developed by Rennes University Hospital, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing alternatives. The primary risk is the lack of clear revenue data and key trial results, which may limit its market visibility and investor confidence.
At a glance
| Generic name | TFP block ropivacaine |
|---|---|
| Sponsor | Rennes University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Analgesia Evaluation of an Ultrasound-guided Technique for Inguinal Hernia Surgery in Children in Children (PHASE4)
- Ultrasound TFP (Transversalis Fascia Plane) for Analgesia After Iliac Crest Bone Graft Harvest (PHASE4)
- Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TFP block ropivacaine CI brief — competitive landscape report
- TFP block ropivacaine updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI